Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Security Union: Commission welcomes adoption of new measures denying terrorists and criminals the means and space to act

Published

on

Reading Time: 4 minutes

 

Today, the European Parliament adopted two important Security Union legislative initiatives proposed by the Commission on interoperability and explosive precursors. These new measures will allow EU information systems for security, migration and border management to work together more intelligently and will strengthen EU rules on explosive precursors.

Commissioner for Migration, Home Affairs and Citizenship Dimitris Avramopoulos said: “The Security Union is steadily taking shape with a whole range of tools, actions and rules being put in place to protect our citizens on all fronts. I welcome that the European Parliament has given its final green light today to ensure that all our information systems can talk to one another and that terrorists and criminals can no longer get their hands on dangerous chemicals to produce homemade bombs. This is Europe at its best. This is Europe that protects.”

Commissioner for the Security Union Julian King said: “Today’s adoptions mark another important milestone in our work towards an effective and genuine Security Union. Interoperability will help those working in the frontline to keep EU citizens safe – ensuring police and border guards have efficient access to the information they need, including to fight identity fraud, enables them to do their jobs properly. And the new rules on explosive precursors are an important element of our work in closing down the space in which terrorists operate, preventing them from gaining access to the means they use to cause harm.”

Better protecting European citizens has been a political priority since the beginning of the Juncker Commission’s mandate – from President Juncker’s Political Guidelines of July 2014 to the latest State of the Union Address on 12 September 2018. The adopted measures will expedite the ongoing efforts at EU level to improve internal security and close down the space in which criminals and terrorists operate.

The interoperability framework will:

  • Crosscheck existing data with one click through a European search portal: Border guards and police will, on a single screen, be able to carry out and cross-check identity documents against all the relevant EU information systems, in line with their existing access rights;
  • Better detect identity fraud: Border guards and police will soon be able to identify dangerous criminals more easily through a shared biometric matching service that will use fingerprints and facial images to search across existing information systems, and through a common identity repository which will store biographical data of non-EU citizens. In addition, a multiple-identity detector will cross-check and immediately flag anyone who is using fraudulent or multiple identities;
  • Protect fundamental rights: Interoperability does not change the rules on access and purpose limitation relating to the EU’s information systems. Fundamental rights thus remain protected.

While the EU already has strict rules in place on access to chemical precursors that can be used to produce homemade explosives, the strengthened regulation will:

  • Ban additional chemicals: The list of restricted substances has been updated to include sulphuric acid, an ingredient in the explosives used in the attack at the airport and the subway of Brussels in March 2016, as well as ammonium nitrate.
  • Strengthen licensing and screening: Before issuing a license to a member of the general public for buying restricted substances, each Member State will need to check the legitimacy of such a request and perform a careful security screening, including a criminal background check.

Next steps

The Council will now have to adopt the texts of the two new Regulations establishing the framework for the interoperability of EU information systems for security, border and migration management, as well as the strengthened Regulation on the marketing and use of explosives precursors. The texts will then be co-signed by the President of the European Parliament and the rotating Presidency of the Council, published in the Official Journal and will enter into force twenty days later.

The Regulation on explosives precursors will become applicable immediately. The Regulations on interoperability will enable eu-LISA to start developing and rolling-out the technical components for the relevant IT systems. These include the reinforced Schengen Information System (SIS), the existing Visa Information System (VIS), the European Criminal Records Information System (ECRIS-TCN), the EU Entry/Exit System (EES) and the European Travel Information and Authorisation System (ETIAS). The work is expected to be complete by 2023.

Background

The Juncker Commission has prioritised security from day one. The European Agenda on Security guides the Commission’s work in this area, setting out the main actions to ensure an effective EU response to terrorism and security threats, including countering radicalisation, boosting cybersecurity, denying terrorists the means to act as well as improving information exchange. Since the adoption of the Agenda, significant progress has been made in its implementation, paving the way towards an effective and genuine Security Union.

In April 2016, the Commission presented a Communication on stronger and smarter information systems for borders and security, starting a discussion on how to make EU information systems work better in order to enhance border management and internal security.In May 2017, the Commission proposed a new approach to achieve full interoperability of EU information systems for security, border and migration management by 2020 and followed up with legislative proposals in December 2017. The European Parliament and the Council reached political agreement on the Commission’s proposals in February 2019.

In 2013, the EU put in place rules to restrict access to explosive precursors that could be used to make home-made explosives. However, the security threat has been constantly evolving with terrorists using new tactics, and developing new recipes and bomb-making techniques. This is why the Commission proposed to tighten those rules further in April 2018, as part of a wider set of security measures to deny terrorists the means to act. The European Parliament and the Council reached a provisional agreement on the Commission’s proposal on 4 February.


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland

Published

on

Continue Reading

Cannabis

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

Published

on

Continue Reading

Innocan

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Published

on

innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial:-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey

HERZLIYA, Israel and ALGARY, AB, May 9, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan’s innovative therapy provided immediate noticeable pain relief and improved mobility.

Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri’s condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her.

As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed.

“Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia,” commented Iris Bincovich, CEO of Innocan. “Once again, Innocan has shown liposomal-CBD to be effectively active for pain relief and well-being. We see this pre-clinical treatment as strong evidence of liposomal-CBD’s potential to improve the lives of animal patients and potentially human patients.”

“Laminitis is a crippling condition well familiar and common in horses,” said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan. “The disease results in severe pain condition, representing another big market for liposomal-CBD with great potential to treat horses. Innocan is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.”

For further information and a supporting video, please see: https://youtu.be/Hgqh2WOlwJQ?si=oGgSYrGi3rkW-RC

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+1 5162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey-302141590.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania